Diosgenin interferes coronary vasoconstriction and inhibits osteochondrogenic transdifferentiation of aortic VSMC in CRF rats

Manivannan, Jeganathan; Shanthakumar, Janakiraman; Arunagiri, Pandiyan; Raja, Boobalan; Balamurugan, Elumalai

doi:10.1016/j.biochi.2014.03.011

Cited by 18 publications

(11 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, combinations of anticancer drugs with new agents are being investigated to explore a significant prognostic benefit and improve clinical response. To date, diosgenin has been reported to be very effective against arthritis, gastrointestinal disorders, cardiovascular dysfunction, inflammation and cancer [ 17 , 23 , 38 , 39 , 40 ]. The present study established the cardioprotective effects of diosgenin in the model of DOX-induced mice.…”

Section: Discussionmentioning

confidence: 99%

In Vivo Protective Effects of Diosgenin against Doxorubicin-Induced Cardiotoxicity

et al. 2015

View full text Add to dashboard Cite

Doxorubicin (DOX) induces oxidative stress leading to cardiotoxicity. Diosgenin, a steroidal saponin of Dioscorea opposita, has been reported to have antioxidant activity. Our study was aimed to find out the protective effect of diosgenin against DOX-induced cardiotoxicity in mice. DOX treatment led to a significant decrease in the ratio of heart weight to body weight, and increases in the blood pressure and the serum levels of lactate dehydrogenase (LDH), creatine phosphokinase (CPK) and creatine kinase myocardial bound (CK-MB), markers of cardiotoxicity. In the heart tissue of the DOX-treated mice, DOX reduced activities of antioxidant enzymes, including superoxide dismutase (SOD) and glutathione peroxidase (GPx), were recovered by diosgenin. Diosgenin also decreased the serum levels of cardiotoxicity markers, cardiac levels of thiobarbituric acid relative substances (TBARS) and reactive oxygen species (ROS), caspase-3 activation, and mitochondrial dysfunction, as well as the expression of nuclear factor kappa B (NF-κB), an inflammatory factor. Moreover, diosgenin had the effects of increasing the cardiac levels of cGMP via modulation of phosphodiesterase-5 (PDE5) activity, and in improving myocardial fibrosis in the DOX-treated mice. Molecular data showed that the protective effects of diosgenin might be mediated via regulation of protein kinase A (PKA) and p38. Our data imply that diosgenin possesses antioxidant and anti-apoptotic activities, and cGMP modulation effect, which in turn protect the heart from the DOX-induced cardiotoxicity.

show abstract

Section: Discussionmentioning

confidence: 99%

In Vivo Protective Effects of Diosgenin against Doxorubicin-Induced Cardiotoxicity

et al. 2015

View full text Add to dashboard Cite

show abstract

“…In addition, diosgenin (molecular formula, C 27 H 42 O 3 ; molecular weight, 414.61 Da) is an important raw material in the synthesis of steroid agents. Previous studies have demonstrated that diosgenin possesses antitumor (20,21) and antidiabetic (22,23) activities, reduces blood lipid content (24), acts as an anti-inflammatory (25) and vasodilator (26), and protects the myocardium (27). With…”

Section: Introductionmentioning

confidence: 99%

Diosgenin-induced autophagy and apoptosis in a human prostate cancer cell line

Nie

Zhou

Qin³

et al. 2016

Molecular Medicine Reports

View full text Add to dashboard Cite

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperworit Reduction Project (0704-0188), Washington, DC 20503

show abstract

“…To date, in vitro and in vivo experiments have tested 12 natural antioxidants that are also dietary ingredients, including 10-dehydrogingerdione (10-DHGD) 64 , apocynin 18,19 , curcumin 38 , diosgenin 20,21 , ellagic acid 56 , gallic acid 48 , gingko biloba extracts 50 , puerarin 62 , quercetin 25–31 , resveratrol 52 , silybin 38 , and vitamin E 34,35 . Among these compounds, apocynin, diosgenin, quercetin, and vitamin E have been shown by multiple studies to have anti-VC properties.…”

Section: Antioxidants From Natural and Dietary Sources For Treatment mentioning

confidence: 99%

“…Previous studies demonstrated that diosgenin possessed lipid and glucose-lowering effects in addition to anti-inflammatory and antioxidant properties 67 . Manivannan et al found that diosgenin could reduce aortic calcification in CKD rats in a dose-dependent manner by increasing antioxidant enzyme levels, lowering lipid peroxidation 20 , and stimulating endothelial nitric oxide synthase (eNOS) activities, thereby improving coronary reserves 21 . Vitamin E, including lipophilic tocopherols and tocotrienols, is universally found in green vegetables, nuts, eggs, and milk, and has long been known to exhibit strong antioxidant properties.…”

Section: Antioxidants From Natural and Dietary Sources For Treatment mentioning

confidence: 99%

Natural and non-natural antioxidative compounds: potential candidates for treatment of vascular calcification

et al. 2019

View full text Add to dashboard Cite

Vascular calcification (VC) is highly prevalent in patients with advanced age, or those with chronic kidney disease and diabetes, accounting for substantial global cardiovascular burden. The pathophysiology of VC involves active mineral deposition by transdifferentiated vascular smooth muscle cells exhibiting osteoblast-like behavior, building upon cores with or without apoptotic bodies. Oxidative stress drives the progression of the cellular phenotypic switch and calcium deposition in the vascular wall. In this review, we discuss potential compounds that shield these cells from the detrimental influences of reactive oxygen species as promising treatment options for VC. A comprehensive summary of the current literature regarding antioxidants for VC is important, as no effective therapy is currently available for this disease. We systematically searched through the existing literature to identify original articles investigating traditional antioxidants and novel compounds with antioxidant properties with regard to their effectiveness against VC in experimental or clinical settings. We uncovered 36 compounds with antioxidant properties against VC pathology, involving mechanisms such as suppression of NADPH oxidase, BMP-2, and Wnt/β-catenin; anti-inflammation; and activation of Nrf2 pathways. Only two compounds have been tested clinically. These findings suggest that a considerable opportunity exists to harness these antioxidants for therapeutic use for VC. In order to achieve this goal, more translational studies are needed.

show abstract

Diosgenin interferes coronary vasoconstriction and inhibits osteochondrogenic transdifferentiation of aortic VSMC in CRF rats

Cited by 18 publications

References 26 publications

In Vivo Protective Effects of Diosgenin against Doxorubicin-Induced Cardiotoxicity

In Vivo Protective Effects of Diosgenin against Doxorubicin-Induced Cardiotoxicity

Diosgenin-induced autophagy and apoptosis in a human prostate cancer cell line

Natural and non-natural antioxidative compounds: potential candidates for treatment of vascular calcification

Contact Info

Product

Resources

About